Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ethics in Research01:56

Ethics in Research

26.0K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
26.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

503
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
503
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

312
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
312
Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

337
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
337
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

193
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
193

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Psychedelic Therapies Executive Order: On Approval and Clinical Readiness.

JAMA·2026
Same author

Patient Perspectives on Approval Speed vs Evidentiary Certainty in US Cancer Drug Approvals.

JAMA network open·2026
Same author

Timely nudges promote patient portal enrollment and sustained engagement: a randomized controlled trial.

JAMIA open·2026
Same author

eConsent vs traditional consent among prospective biobank participants: a randomized study within a study trial.

npj digital public health·2026
Same author

The arrival of digital twins and in silico trials in drug development.

Nature medicine·2026
Same author

Advancing FDA New Approach Methodologies from animal models through digital twins.

NPJ digital medicine·2026
Same journal

Harm Reduction as an Alternative to Mandated Drug Treatment.

The Hastings Center report·2026
Same journal

Rethinking Mandated Drug Treatment: Why Expanding Freedom Requires Structural Drug Policy Reform.

The Hastings Center report·2026
Same journal

Banning Gender-Affirming Treatment for Minors: The Supreme Court Speaks.

The Hastings Center report·2026
Same journal

Making the Move to a Learning System of Research Ethics.

The Hastings Center report·2026
Same journal

Musical Performance and Biomedical Human Enhancement: Ethnographic Perspectives on Bioethical Questions.

The Hastings Center report·2026
Same journal

Transformed but Not Cured: The Ethics of Describing Gene-Editing Therapy for Sickle Cell Disease.

The Hastings Center report·2026
See all related articles

Related Experiment Video

Updated: Mar 1, 2026

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.8K

Regulating Research with Biospecimens under the Revised Common Rule.

Holly Fernandez Lynch, Michelle N Meyer

    The Hastings Center Report
    |May 26, 2017
    PubMed
    Summary
    This summary is machine-generated.

    Researchers anticipated changes to biospecimen research regulations under the Common Rule. The Final Rule did not include controversial changes, but new consent options offer little practical benefit, leaving key issues unresolved.

    More Related Videos

    Working with Human Tissues for Translational Cancer Research
    07:48

    Working with Human Tissues for Translational Cancer Research

    Published on: November 26, 2015

    10.4K
    Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications
    06:42

    Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications

    Published on: September 2, 2025

    670

    Related Experiment Videos

    Last Updated: Mar 1, 2026

    Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
    08:01

    Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

    Published on: November 30, 2022

    5.8K
    Working with Human Tissues for Translational Cancer Research
    07:48

    Working with Human Tissues for Translational Cancer Research

    Published on: November 26, 2015

    10.4K
    Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications
    06:42

    Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications

    Published on: September 2, 2025

    670

    Area of Science:

    • Bioethics
    • Regulatory Science
    • Biomedical Research

    Background:

    • The Common Rule governs human subjects research in the U.S.
    • Secondary research with biospecimens faced potential regulatory changes impacting consent requirements.
    • Concerns were raised about the impact of new regulations on biospecimen research.

    Purpose of the Study:

    • To analyze the implications of the 2011 proposed changes to the Common Rule regarding biospecimen research.
    • To assess the impact of the Final Rule on consent waivers and broad consent for biospecimen research.
    • To evaluate the long-term regulatory landscape for secondary use of biospecimens.

    Main Methods:

    • Analysis of regulatory proposals and the final Common Rule.
    • Review of public comments and expert opinions on biospecimen research regulations.
    • Assessment of the practical utility of new consent provisions for researchers.

    Main Results:

    • The Final Rule omitted significant proposed changes to secondary research with nonidentifiable biospecimens.
    • New broad consent options under the Final Rule present limited advantages for researchers.
    • The debate regarding the inherent identifiability of biospecimens remains unresolved.

    Conclusions:

    • While immediate regulatory threats were averted, the Final Rule offers minimal practical improvements for biospecimen research.
    • The core issues surrounding biospecimen identifiability and consent require further regulatory attention.
    • Future policy development must address the complexities of secondary biospecimen research to support scientific advancement.